| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C21H23N4O7PS2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
GSK2983559 free acid is an orally active, potent inhibitor of receptor-interacting protein 2 (RIP2) kinase. It can block many proinflammatory cytokine responses both in vivo and in human inflammatory bowel disease explant samples[1]. It is supplied as a light yellow to yellow solid (C21H23N4O7PS2, MW 538.53) at 99.49% purity.
Physical & Chemical Properties
| CAS Number | 1579965-12-0 |
|---|---|
| Molecular Formula | C21H23N4O7PS2 |
| Molecular Weight | 538.53 g/mol |
| Purity | 99.49% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | CC(C)(C)S(C(C(OCCOP(O)(O)=O)=CC1=NC=N2)=CC1=C2NC3=CC(N=CS4)=C4C=C3)(=O)=O |
| Target | RIPK2 |
| Signaling Pathway | Apoptosis |
| Solubility | In Vitro: DMSO: 5 mg/mL (9.28 mM; Requires sonication and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 5 mg/mL (9.28 mM) | requires sonication and warming and heat to 80°C; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
In THP-1 cells, GSK2983559 (1-1024 nM; 2 h) blocks IL-8 induced by MDP[2].
Cell Viability Assay[2]
| Cell Line | THP-1 cells |
|---|---|
| Concentration | 1-1024 nM |
| Incubation Time | 2 hours |
| Result | Inhibited IL-8 production with an IC50 of 1.34 nM. |
In Vivo
In mouse, GSK2983559 (oral gavage; 3 and 10 mg/kg; once) effectively inhibits IL-6 induced by MDP[2].
| Animal Model | C57BL/6 mice (female) injected with MDP (100 μg)[2] |
|---|---|
| Dosage | 3 and 10 mg/kg |
| Administration | Oral gavage; 3 and 10 mg/kg; once |
| Result | Suppressed serum IL-6 levels in a dose-dependent manner. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Patent. US20250241918A1.
SSRN. 2025 Feb 13.
